PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata

NCT01629563 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

451

Enrollment

INDUSTRY

Sponsor class

Conditions

Uterine Fibroids

Interventions

DRUG: PGL4001 5 mg
DRUG: PGL4001 10 mg

Sponsor

PregLem SA